BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 2581393)

  • 1. [Tumor marker diagnosis in non-seminomatous testicular tumors using human chorionic gonadotropin (HCG) and alpha fetoprotein (AFP)].
    Boewer C; Nawka S; Fleck H; Uibel M; Immer U; Schmidt HE; Herzmann H; Pilgrim G; Ziegenbein R
    Z Urol Nephrol; 1985 Feb; 78(2):77-86. PubMed ID: 2581393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of human chorionic gonadotropin and alpha fetoprotein in benign and malignant testicular disorders.
    Moore MR; Garrett PR; Walton KN; Waldmann TA; McIntire RK; Vogel CL
    Surg Gynecol Obstet; 1978 Aug; 147(2):167-74. PubMed ID: 80036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
    Tröbs RB; Krauss M; Geyer C; Tannapfel A; Körholz D; Hirsch W
    Klin Padiatr; 2007; 219(3):146-51. PubMed ID: 17525908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor markers in testicular cancer].
    Mann K
    Urologe A; 1990 Mar; 29(2):77-86. PubMed ID: 2158684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors.
    Lange PH
    Natl Cancer Inst Monogr; 1978 Dec; (49):215-7. PubMed ID: 86163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical presentation of testicular germinal cancer].
    Fernández Gómez JM; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; Escaf Barmadah S; García Rodríguez J; Pérez García FJ; Rodríguez Faba O; Jalón Monzón A
    Arch Esp Urol; 2002 Oct; 55(8):915-22. PubMed ID: 12455282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors.
    Vogelzang NJ; Lange PH; Goldman A; Vessela RH; Fraley EE; Kennedy BJ
    Cancer Res; 1982 Nov; 42(11):4855-61. PubMed ID: 6181870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers--personal experience. Multidisciplinary treatment of disseminated germ cell tumor in full use of tumor markers].
    Tobisu K
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1221-6. PubMed ID: 1711304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on the tumor markers in the germinal testicular tumors. Cellular localization of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG) and carcinoembryonic antigen (CEA) in germinal testicular tumors using an indirect immunoperoxidase method].
    Miki T
    Nihon Hinyokika Gakkai Zasshi; 1984 Mar; 75(3):503-22. PubMed ID: 6206269
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
    Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
    Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
    Neumann A; Keller T; Jocham D; Doehn C
    Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
    Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of markers AFP, HCG and LDH in advanced germ cell tumors before and after cytostasis resp.
    Jaeger N; Vahlensieck W
    Prog Clin Biol Res; 1985; 203():107-16. PubMed ID: 2421323
    [No Abstract]   [Full Text] [Related]  

  • 14. [Importance of the intracellular detection of alpha-fetoprotein and beta-human chorionic gonadotropin in a testicular tumor using immunoperoxidase].
    Schwarz HP; Susani M; Kratzik C; Studler G; Krisch K; Aiginger P
    Wien Klin Wochenschr; 1984 Mar; 96(6):230-4. PubMed ID: 6204462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer.
    Javadpour N; McIntire KR; Waldmann TA
    Natl Cancer Inst Monogr; 1978 Dec; (49):209-13. PubMed ID: 86162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum alpha-fetoprotein and chorionic gonadotropin in response to cancer therapy.
    Nisselbaum JS; Bosl GJ; Golbey RB; Schwartz DC; Schwartz MK
    Ann Clin Lab Sci; 1984; 14(3):179-88. PubMed ID: 6203466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of radioimmunoassay of human chorionic gonadotropin and alpha fetoprotein in nonseminomatous germ cell tumors of the testis.
    Kausitz J; Hupka S; Cerný V; Bohunický L; Korec S
    Neoplasma; 1980; 27(3):321-7. PubMed ID: 6161314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological markers and germinal tumors of the testis. Value and limitations of the assay of chorionic gonadotrophin hormone and alpha-fetoprotein].
    Bassoulet J; Pabot du Chatelard P; Ricordel I; Auberget JL; Guillemot MC; Merrer J; Timbal Y
    J Urol (Paris); 1988; 94(8):393-6. PubMed ID: 2467947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of tumor markers in the treatment of germ cell tumor].
    Niwakawa M; Tobisu K
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Delayed retroperitoneal lymph node excision in treatment of advanced non-seminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor].
    Otto T; Goepel M; Seeber S; Rübben H
    Urologe A; 1993 May; 32(3):189-93. PubMed ID: 7685554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.